News

Sigvotatug Vedotin in Previously Treated Metastatic Non-Squamous Non-Small Cell Lung Cancer: Topline Results from the Phase 3 SigVie-002 Study

Advancing Next-Generation Radiopharmaceuticals through Regio-Selective Conjugation

AmMax Bio, a private clinical-stage biopharmaceutical company developing an innovative portfolio of antibody-drug conjugates (ADC) in oncology, and Lonza, the world’s leading contract development...

TLX591-Tx in Combination With Standard-of-Care in Metastatic Castration-Resistant Prostate Cancer: Results From Part 1 of the Phase 3 ProstACT Global Study

Advances, Sequencing Challenges, and Real-World Integration of ADCs in Breast Cancer: Insights from ASCO 2026

In a landmark advancement for patients with ultra-rare blood cancers, the U.S. Food and Drug Administration (FDA) has approved pivekimab sunirine (Decnupaz™; AbbVie), previously known as IMGN632, marking the first and only antibody-drug conjugate (ADC) authorized for the treatment of adult patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN).

Datopotamab deruxtecan: First TROP2-Directed ADC Approved for First-Line Treatment of mTNBC in Patients Ineligible for Immunotherapy

Becotatug Vedotin: First EGFR-Targeted ADC Approved in China for Recurrent or Metastatic Nasopharyngeal Carcinoma

This year, the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting will feature a breadth of new data on emerging antibody-drug conjugates (ADCs) and T-cell engagers (TCEs), particularly across solid tumors and hematologic malignancies. This article synthesizes pivotal findings from AbbVie’s next-generation ADC and TCE platforms—including SEZ6-, PSMA/STEAP1-, c-Met-, and FRα-targeted ADCs—alongside immune checkpoint inhibitor combinations and real-world evidence.

Amanitin-Based ADCs: Transforming Mushroom Toxin into Precision Oncology